Related references
Note: Only part of the references are listed.A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis
Stephen R. Brand et al.
CLINICAL INFECTIOUS DISEASES (2021)
Oral Ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis
Nkechi Azie et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
Prognosis and Long-Term Outcome of Women With Idiopathic Recurrent Vulvovaginal Candidiasis Caused by Candida albicans
Laura M. Collins et al.
JOURNAL OF LOWER GENITAL TRACT DISEASE (2020)
Vulvovaginal Candidiasis: A Current Understanding and Burning Questions
Hubertine M. E. Willems et al.
JOURNAL OF FUNGI (2020)
A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis
Stephen R. Brand et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2018)
Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species
J. D. Sobel et al.
EXPERT OPINION ON PHARMACOTHERAPY (2018)
Global burden of recurrent vulvovaginal candidiasis: a systematic review
David W. Denning et al.
LANCET INFECTIOUS DISEASES (2018)
Long-Term Outcomes of Women With Recurrent Vulvovaginal Candidiasis After a Course of Maintenance Antifungal Therapy
Tess Crouss et al.
JOURNAL OF LOWER GENITAL TRACT DISEASE (2018)
Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong In Vitro Activity against Candida glabrata and C. krusei Isolates Clinically Resistant to Azole and Echinocandin Antifungal Compounds
W. A. Schell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
Romuald Bellmann et al.
INFECTION (2017)
Recurrent vulvovaginal candidiasis
Freida Blostein et al.
ANNALS OF EPIDEMIOLOGY (2017)
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
Peter G. Pappas et al.
CLINICAL INFECTIOUS DISEASES (2016)
Recurrent vulvovaginal candidiasis
Jack D. Sobel
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2016)
Evaluation of VT-1161 for Treatment of Coccidioidomycosis in Murine Infection Models
Lisa F. Shubitz et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Efficacy of the Clinical Agent VT-1161 against Fluconazole-Sensitive and -Resistant Candida albicans in a Murine Model of Vaginal Candidiasis
E. P. Garvey et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
The Clinical Candidate VT-1161 Is a Highly Potent Inhibitor of Candida albicans CYP51 but Fails To Bind the Human Enzyme
A. G. S. Warrilow et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Design and optimization of highly-selective fungal CYP51 inhibitors
William J. Hoekstra et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis
JD Sobel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
